Novartis to file for new Lucentis (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness
- In the Phase III RAINBOW study, despite marginally missing statistical significance for the primary endpoint of demonstrating superiority of Lucentis to laser surgery, Lucentis was shown to be an efficacious, safe and well-tolerated treatment for infants with ROP
- Laser surgery, the current standard of care for ROP in infants, destroys diseased retinal tissue responsible for elevated vascular endothelial growth factor (VEGF) whereas Lucentis is an anti-VEGF that directly targets and reduces VEGF
- With 80% of patients achieving treatment success with 0.2mg Lucentis versus 66% with laser, these data are clinically relevant
- Novartis plans to file ex-US for a new indication in ROP to bring transformative treatment to premature infants facing severe vision loss - the first anti-VEGF product to seek an ROP indication
Basel, September 22, 2018 - Novartis today announced results from a Phase III study of Lucentis (ranibizumab) versus laser surgery (the current standard of care) at the 18th Congress of the European Society of Retina Specialists (EURETINA) in premature infants with retinopathy of prematurity (ROP), a rare disease but a leading cause of childhood blindness , . Unlike laser surgery, which damages eye tissue and can be associated with significant complications such as high myopia, Lucentis pharmacologically targets and reduces the elevated intraocular level of vascular endothelial growth factor (VEGF), which is the underlying cause of the condition , , .
Although the RAINBOW Phase III study marginally missed statistical significance for the primary endpoint (p=0.0254, as opposed to the significance level of p=0.025), the difference in treatment success between the Lucentis 0.2mg and 0.1mg groups compared to laser surgery (80%, 75% and 66.2% respectively) is nevertheless considered clinically relevant by Novartis. Based on the favorable benefit-risk profile, Novartis plans to file for a new indication for Lucentis for the treatment of ROP to support this rare but important patient population.
"Laser surgery, the current standard of care, works by destroying the tissue in the eye that contributes to the elevation of VEGF. While it is an effective treatment, there is a clear unmet need for innovative ways to treat ROP without destroying retinal tissue. Lucentis demonstrated in the RAINBOW study that it is an efficacious and well tolerated option for the treatment of ROP that may offer new hope to parents of this vulnerable patient population," said Professor Andreas Stahl, Senior Physician in Retinal Surgery and Head of the Angiogenesis Research Group at the Eye Center, University of Freiburg, Germany.
Retinopathy of prematurity affects premature infants in both developed and developing countries, with an estimated 23,800 to 45,600 infants newly diagnosed with irreversible vision impairment from ROP each year. Caused by the abnormal development of retinal blood vessels in premature infants, disease progression is due to high levels of a growth factor called VEGF. After premature birth, high VEGF levels can cause an infant’s blood vessels in the retina to develop abnormally, which may lead to structural abnormalities such as retinal detachment, resulting in vision loss or blindness , .
"The RAINBOW study is part of our ongoing commitment to addressing the most urgent needs in eye care. We look forward to filing outside the US for an indication in ROP, which may bring us one step closer to reimagining care for these premature infants," said Dirk Sauer, Development Unit Head, Novartis Ophthalmology.
Lucentis (ranibizumab injection), the first anti-vascular endothelial cell growth factor (anti-VEGF) therapy licensed for ophthalmic use, revolutionized the treatment of nAMD and has helped reduce blindness due to nAMD by 50% in several parts of the world. More than a decade of innovation and six indications (nAMD, DME, BRVO, CRVO, mCNV and other CNV) later, Lucentis continues to preserve and resolve vision for patients around the globe. We continue to investigate the possibility of Lucentis to transform the treatment of even the youngest, most vulnerable patients.
Lucentis is available in more than 110 countries and is supported by a portfolio of 251 sponsored clinical studies and extensive real-world experience. The Lucentis clinical development program has enrolled more than 205,000 patients across indications with 5.4 million patient-treatment years of exposure since the therapy’s launch in the United States in 2006. Lucentis was developed by Genentech and Novartis. Genentech has the rights to Lucentis in the United States. Novartis has rights in the rest of the world. Lucentis is a registered trademark of Genentech Inc.
Retinopathy of prematurity (ROP) is a rare and potentially blinding disease caused by abnormal development of retinal blood vessels in premature babies (preterm infants) , , . The retina is the inner layer of the eye that receives light and turns it into visual messages that are sent to the brain.
The retina develops late in the womb and very premature babies may have incomplete development of blood vessels needed to provide oxygen , . VEGF is an important regulator of the development of new blood vessels (known as angiogenesis) and plays a key role in the progression of ROP. If the blood vessels do not develop normally during ROP, they can exert traction on the retina and lead to macular dragging, retinal detachment or other structural abnormalities resulting in vision loss or potentially blindness.
The RAINBOW study, which was conducted in 26 countries,is a randomized, open-label, controlled, multicenter study designed to compare the efficacy and safety of intravitreal Lucentis (ranibizumab) with laser surgery in 225 patients with ROP. The trial compared two different concentrations of Lucentis, 0.1 mg and 0.2 mg, to the current standard of care, laser surgery. The outcomes of the study were measured at 24 weeks after starting the trial. A long-term extension trial is currently underway and expected to conclude by Q4 of 2022. The exact conclusion date is to be confirmed.